

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP	
<b>2. Address</b> Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>	
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____	
<b>4a. Contact Name</b> Ms. <u>Sarah Arbes</u>	<b>b. Telephone Number</b> <u>2022467003</u>
<b>c. E-mail</b> <u>sarah.arbes@astrazeneca.com</u>	<b>5. Senate ID#</b> <u>54073-12</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP	<b>6. House ID#</b> <u>349750000</u>

**TYPE OF REPORT** 8. Year 2024 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center"><b>12. Lobbying</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>950,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Sarah Arbes Date 7/22/2024 3:33:10 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 7085 Biosecure Act  
 H.R. 5539/S.3131 ORPHAN Cures Act, amending orphan drug exclusion in IRA  
 Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties  
 issues related to expanding orphan drug exclusion in IRA  
 Reauthorization of newborn screening programs  
 Reauthorization of the pediatric priority review voucher program  
 FDA modernization policy issues  
 Issues related to FDA proposed regulation of lab developed tests  
 Medicare drug price negotiation  
 Medicaid Drug Rebate Program proposed rule  
 PBM Reform (misc. bills)  
 Issues related to reform of pharmacy benefit managers  
 General issues related to health equity in rare disease and clinical trials  
 General issues related to diagnostics for patients with rare diseases  
 General issues related to rare disease and orphan drugs  
 Issues related to drug pricing  
 Issues related to the price and manufacture of inhaled medicines  
 Issues related to importation of drugs  
 Issues related to march-in rights

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 5539/S. 3131 Orphan Cures Act, (amdending orphan drug exclusion in IRA)  
 H.R. 3876 Access to Genetic Counselor Services Act of 2023  
 H.R. 2666 Medicaid VBPs for Patients Act  
 Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No 117-169)  
 Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169  
 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure  
 Medicaid Drug Rebate Program Proposed Rule  
 Centers for Medicare and Medicaid Innovation (CMMI) policy issues  
 Value-based payment arrangements  
 Medicare patient access to rare disease therapies, Part B and Part D drugs  
 Medicaid Drug Rebate Program proposed rule, specifically the stacking rule  
 Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies  
 General issues related to diagnostic reimbursement  
 Efforts to improve coding, coverage, and access for rare disease therapies

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

E-labeling

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 1350, Camerons Law  
 S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023.  
 Issues related to the Orphan Drug Tax Credit;  
 issues related to the deduction of research and development expenditures

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
Issues related to pharmaceutical intellectual property (IP)
General patent issues

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Art	Motta			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

--

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

--

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
<b>1</b>			<b>3</b>		
<b>2</b>			<b>4</b>		

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

--	--	--	--	--	--	--	--	--

### AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	
	City				City State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

### FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			
	City			City State Country		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5  
2 4 6

### CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)